Clinical Trials Logo

Recurrent Cutaneous Melanoma clinical trials

View clinical trials related to Recurrent Cutaneous Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04221438 Active, not recruiting - Clinical trials for Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Start date: September 22, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.

NCT ID: NCT02581930 Active, not recruiting - Metastatic Melanoma Clinical Trials

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Start date: August 17, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02506153 Active, not recruiting - Clinical trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Start date: November 10, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether high-dose recombinant interferon alfa-2B or ipilimumab is more effective than pembrolizumab in treating patients with melanoma.